Prediction of remission of depression with clinical variables, neuropsychological performance, and serotonergic/dopaminergic gene polymorphisms.
Hum Psychopharmacol
; 27(6): 577-86, 2012 Nov.
Article
em En
| MEDLINE
| ID: mdl-24446536
ABSTRACT
OBJECTIVE:
The aim of our work is to study the possible role of clinical variables, neuropsychological performance, and the 5HTTLPR, rs25531, and val108/58Met COMT polymorphisms on the prediction of depression remission after 12 weeks' treatment with fluoxetine. These variables have been studied as potential predictors of depression remission, but they present poor prognostic sensitivity and specificity by themselves.METHODS:
Seventy-two depressed patients were genotyped according to the aforementioned polymorphisms and were clinically and neuropsychologically assessed before a 12-week fluxetine treatment.RESULTS:
Only the La allele of rs25531 polymorphism and the GG and AA forms of the val 108/158 Met polymorphism predict major depressive disorder remission after 12 weeks' treatment with fluoxetine. None of the clinical and neuropsychological variables studied predicted remission.CONCLUSIONS:
Our results suggest that clinical and neuropsychological variables can initially predict early response to fluoxetine and mask the predictive role of genetic variables; but in remission, where clinical and neuropsychological symptoms associated with depression tend to disappear thanks to the treatment administered, the polymorphisms studied are the only variables in our model capable of predicting remission. However, placebo effects that are difficult to control require cautious interpretation of the results.
Buscar no Google
Base de dados:
MEDLINE
Assunto principal:
Polimorfismo Genético
/
Catecol O-Metiltransferase
/
Fluoxetina
/
Inibidores Seletivos de Recaptação de Serotonina
/
Transtorno Depressivo Maior
/
Proteínas da Membrana Plasmática de Transporte de Serotonina
/
Antidepressivos
Tipo de estudo:
Clinical_trials
/
Diagnostic_studies
/
Prognostic_studies
/
Risk_factors_studies
Limite:
Adult
/
Female
/
Humans
/
Male
/
Middle aged
País/Região como assunto:
Mexico
Idioma:
En
Revista:
Hum Psychopharmacol
Assunto da revista:
PSICOFARMACOLOGIA
Ano de publicação:
2012
Tipo de documento:
Article
País de afiliação:
México